Presentation (CTI)

OBJECTIVES: This study estimated the budget impact of introducing the respiratory syncytial virus prefusion F protein (RSVpreF) maternal vaccine (MV) for disease prevention among infants in Colombia.
METHODS: We developed a cohort-based model to compare clinical outcomes and economic costs of two strategies: RSVpreF MV versus no intervention (NI). The model adopted the Colombian healthcare system perspective and analyzed outcomes over a 5-year horizon, incorporating annual birth cohorts and applying a 5 % discount rate. Health outcomes included outpatient visits, hospitalizations, and deaths related to RSV. An uptake rate of 86.7 % was assumed, based on the national maternal influenza immunization program. We derived clinical effectiveness, utilities, and cost inputs from key clinical trials, published literature, PAHO records, and national databases. Prices were expressed in 2024 USD (4,020 COP = 1 USD). We conducted robustness checks using one-way sensitivity analysis (OWSA) to assess uncertainties in vaccine effectiveness, costs, RSV incidence, and hospitalization rates.
RESULTS: The introduction of RSVpreF MV over five years could prevent approximately 180,000 RSV cases, with 18 % involving hospitalizations, and avert up to 540 RSV-related deaths. These outcomes translate into medical care savings of $ 60 million. The total cost of vaccine implementation was estimated at $ 77 million, resulting in a net budget impact of 17 million USD over the study period. The average annual cost per woman of reproductive age was $ 0.24. Sensitivity analysis showed that results were most affected by ± 25 % variations in vaccine effectiveness, vaccination costs, and RSV-related hospitalization incidence and costs.
CONCLUSIONS: With a manageable budgetary impact, the introduction of RSVpreF MV in Colombia must significantly reduce RSV-related cases, hospitalizations, and deaths. At a minimal cost per woman, this strategy supports its inclusion in national immunization programs to improve infant health outcomes and optimize healthcare system expenditures.